Table 2.
Analgesic treatment history
| Patients (N = 30) | |
|---|---|
| Maintenance treatment, n (%) | |
| Fentanyl transdermal system | 8 (27) |
| Methadone | 3 (10) |
| Oxycodone controlled release | 3 (10) |
| Fentanyl | 2 (7) |
| Hydrocodone and acetaminophen | 2 (7) |
| Hydromorphone extended release | 2 (7) |
| Morphine sulfate controlled release or extended release | 2 (7) |
| Oxycodone | 2 (7) |
| Oxymorphone extended release | 2 (7) |
| Buprenorphine transdermal system | 1 (3) |
| Hydromorphone | 1 (3) |
| Pregabalin | 1 (3) |
| Tizanidine | 1 (3) |
| Breakthrough pain treatment, n (%) | |
| Fentanyl buccal tablet | 12 (40) |
| Fentanyl oral transmucosal lozenge | 6 (20) |
| Fentanyl sublingual tablet | 2 (7) |
| Hydrocodone and acetaminophen | 2 (7) |
| Oxycodone | 2 (7) |
| Oxymorphone immediate release | 2 (7) |
| Buprenorphine | 1 (3) |
| Morphine sulfate extended release | 1 (3) |
| Oxycodone and acetaminophen | 1 (3) |
| Tramadol extended release | 1 (3) |